![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Chinese Regulators Seek Response to Modified Registration Rules
Chinese Regulators Seek Response to Modified Registration Rules
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/StackofFolders.gif?t=1433943470&width=430)
August 12, 2016
The Chinese FDA has made sweeping reforms to the country’s nine-year-old drug registration rules, looking for industry feedback on a range of drug approval related revisions.
The regulator published a total of 147 modifications to drug registration rules, with the goal of increasing approval efficiency and decreasing its backlog of applications, according to a summary by law firm Ropes & Gray. These changes affect everything from data submissions to the renewal process.
Under the revisions, new drug candidates should demonstrate a clinical advantage over existing products to encourage drug manufacturers and discourage remarketing products with minute changes.
Upcoming Events
-
21Oct